EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Evaluating effectiveness of risk minimization through healthcare professional surveys: A review of post‐authorization studies, 2022–2024

Kexin Zhu, William A Blumentals, Froilan G Celzo, G Caleb Alexander, Lingyun Zhou, Juhaeri Juhaeri, Corinne Jouquelet-Royer, Jian-Yu E iD

British Journal of Clinical Pharmacology · 2026

DOI: 10.1002/bcp.70647 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Kexin Zhu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Epidemiology and Benefit-Risk, Sanofi, Morristown, New Jersey, USA. Hauptthemen laut MEDLINE: Health Personnel, Product Surveillance, Postmarketing, Drug-Related Side Effects and Adverse Reactions, Risk Evaluation and Mitigation. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sanofi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Risk minimization measures (RMMs) are key regulatory tools to ensure safe medicinal product use. Regulatory guidelines recommend pre‐specifying the targets, or ‘thresholds’, for assessing RMM effectiveness. We aimed to review recent industry‐sponsored post‐authorization safety studies (PASS) that evaluated the effectiveness of RMMs, focusing on the use and justification of predefined thresholds.

Methods

We searched the Heads of Medicines Agencies‐European Medicines Agency Catalogue to identify PASS evaluating the effectiveness of RMM through knowledge‐based surveys of healthcare professionals. A total of 17 eligible studies in 2022–2024 were included in the descriptive analysis.

Results

All studies used cross‐sectional designs, and 70.6% were Category 3 PASS. Only 29.4% evaluated RMM effectiveness within the guideline‐recommended time frame (12–24 months) following the launch and regulatory implementation of RMMs. Nearly all studies (16 of 17, 94.1%) predefined effectiveness thresholds. Overall, thresholds ranged from 60% to 80%, with the majority (88.2%) being set at 80%. Thresholds for assessing awareness, knowledge, utilization and behaviours were set at 80%, 80%, 60%–80% and 75%–80%, respectively. However, only eight studies (47.1%) provided rationales for threshold determination. Among them, six studies justified thresholds based on success rates applied in comparable studies or regulatory guidance, while two relied on subjective criteria without specifying prior knowledge, experience or established scientific evidence.

Conclusion

Our findings suggest that although most industry‐sponsored PASS evaluating RMM effectiveness included predefined thresholds, these were often applied to the knowledge indicator rather than awareness, utilization and behaviour indicators. Notably, only about half of the studies provided clear justifications for threshold selection. Clear success threshold justifications are essential for interpreting RMM effectiveness.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Health PersonnelProduct Surveillance, PostmarketingDrug-Related Side Effects and Adverse ReactionsRisk Evaluation and MitigationHumansSurveys and Questionnaires

Stichwörter der Autor:innen

effectivenesspost‐authorization safety studyrisk managementrisk minimization measuresurvey

Autor:innen und Institutionen

  • Epidemiology and Benefit-Risk, Sanofi, Morristown, New Jersey, USA.
  • Patient Safety and Pharmacovigilance, Sanofi, Amsterdam, The Netherlands.
  • Center for Drug Safety and Effectiveness, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
  • Patient Safety and Pharmacovigilance, Sanofi, Shanghai, China.
  • Patient Safety and Pharmacovigilance, Sanofi, Paris, France.
  • Epidemiology and Benefit-Risk, Sanofi, Cambridge, Massachusetts, USA.

ORCID-Profile: Jian-Yu E

Förderung

  • Sanofi

Zitieren

APA

Zhu, K., Blumentals, W. A., Celzo, F. G., Alexander, G. C., Zhou, L., Juhaeri, J., Jouquelet-Royer, C., & E, J. Y. (2026). Evaluating effectiveness of risk minimization through healthcare professional surveys: A review of post‐authorization studies, 2022–2024. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70647

Vancouver

Zhu K, Blumentals WA, Celzo FG, Alexander GC, Zhou L, Juhaeri J, et al. Evaluating effectiveness of risk minimization through healthcare professional surveys: A review of post‐authorization studies, 2022–2024. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70647

BibTeX
@article{Zhu2026,
  author = {Zhu, Kexin and Blumentals, William A and Celzo, Froilan G and Alexander, G Caleb and Zhou, Lingyun and Juhaeri, Juhaeri and Jouquelet-Royer, Corinne and E, Jian-Yu},
  title = {Evaluating effectiveness of risk minimization through healthcare professional surveys: A review of post‐authorization studies, 2022–2024},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/bcp.70647}
}
Kostenlos starten →